Skip to main content

Advertisement

Table 1 FFP administered in relation to the three approaches to classifying the circumstances of administrationa

From: A national study of plasma use in critical care: clinical indications, dose and effect on prothrombin time

Variable FFP units
(median, first to third quartile)
FFP volume, ml
(median, first to third quartile)
FFP dose, ml kg-1
(median, first to third quartile)
Reason given by clinician at time of FFP transfusion
   Coagulopathy with bleeding (n = 185) 3 (2 to 4) 875 (558 to 1104) 11.1 (7.8 to 15.3)
   Coagulopathy without bleeding (n = 138) 2 (2 to 4) 561 (509 to 854) 8.9 (6.8 to 13.1)
   No bleeding prior to procedure (n = 59) 2 (2 to 4) 560 (528 to 1017) 9.8 (6.9 to 13.0)
   P value for differences across groups <0.0001 <0.0001 0.009
   All (N = 404) 3 (2 to 4) 736 (536 to 1092) 10.2 (7.0 to 14.1)
Clinically significant haemorrhage recorded on day of transfusion
   No (n = 215) 2 (2 to 4) 561 (517 to 1017) 9.1 (6.7 to 13.2)
   Yes (n = 189) 3 (2 to 4) 875 (558 to 1100) 11.1 (7.9 to 14.7)
   P value for differences across groups <0.0001 <0.0001 0.006
Use of FFP in relation to occurrence of PT prolongation during ICU admission
FFP administered but no PT prolongation occurred at any time during ICU admission (n = 64) 2 (2 to 4) 568 (502 to 936) 8.5 (5.7 to 12.6)
PT prolongation occurred during ICU admission, but FFP administered out with an episode of PT prolongation (n = 63) 2 (2 to 4) 570 (535 to 1077) 8.6 (6.3 to 13.7)
FFP administered during an episode of PT prolongation (n = 277) 3 (2 to 4) 806 (542 to 1092) 10.8 (7.3 to 14.4)
P value for differences across groups 0.11 0.037 0.014
  1. aFFP, fresh frozen plasma; PT, prothrombin time; ICU, intensive care unit.